What do systematic reviews say?

Early (less than seven days following birth) higher vs lower sodium intake

• Higher versus lower sodium intake for preterm infants 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in headache ( compared with placebo plus rehabilitation (low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 1.73 [0.92, 3.24]
  1 study · 53 participants
  Low

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in rash ( compared with placebo plus rehabilitation (low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 3.12 [0.35, 28.06]
  1 study · 53 participants
  Low

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

The review found no eligible studies for this question.

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: 1.25 mg/day plus rehabilitation vs placebo plus rehabilitation

Summary of findings: 1.25 mg/day plus rehabilitation showed no clear difference in symptom free with activities of daily living (patient rated) ( compared with placebo plus rehabilitation (low certainty).

• Topical glyceryl trinitrate for rotator cuff disease 2009 · Cochrane Headline outcomes only
  RR 1.92 [0.92, 4.1]
  1 study · 57 participants
  Low

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 272 participants
  Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in adverse events Number of participants reporting ≥ 1 serious adverse… compared with placebo (moderate certainty).

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  RR 0.86 [0.71, 1.05]
  1 study · 304 participants
  Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in deaths Number of deaths compared with placebo (moderate certainty).

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  RR 0.84 [0.52, 1.34]
  1 study · 304 participants
  Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 280 participants
  Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in progression to Alzheimer's disease Number of people progressing to AD compared with placebo (moderate certainty).

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  RR 1.03 [0.79, 1.35]
  1 study · 516 participants
  Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

The review found no eligible studies for this question.

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 516 participants
  GRADE not reported

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in death Number of deaths over 36 months compared with placebo (moderate certainty).

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  RR 1.01 [0.3, 3.44]
  1 study · 516 participants
  Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

The review found no eligible studies for this question.

• Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  15 participants
  Very low

HC (13.5 mg/m²/day to 15.5 mg/m²/day): high morning dose vs high evening dose

The review found no eligible studies for this question.

• Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found